Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187842 | 0.92 | KMT2A (0.44) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL4179492 | 0.92 | KMT2A (0.44) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL4185656 | 0.90 | SLC7A5 (0.47) | SLC7A5CYP4F2CYP4A11MMP1MMP3 | |
| SCHEMBL4396674 | 0.86 | KMT2A (0.45) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL557437 | 0.86 | KMT2A (0.48) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL24588993 | 0.86 | KMT2A (0.49) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL10099806 | 0.85 | LTA4H (0.44) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL557417 | 0.85 | LTA4H (0.44) | KMT2AMEN1ALDH1A1HPGDTLR2 | |
| SCHEMBL15387350 | 0.85 | KMT2A (0.58) | KMT2AMEN1ALDH1A1HPGDCCKBR | |
| SCHEMBL15387284 | 0.85 | KMT2A (0.58) | KMT2AMEN1ALDH1A1HPGDCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024390-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-8796205-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2014-08-05 | — | — | US | disclosed |
| US-20090105121-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-2024390-A1 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007128815-A1 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105121-A1 | Insulin Derivative | INSR, IAPP, GPR119 | KMT2A 4779/4885SLC7A5 357/4885MEN1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.